Kaplan-Meier curves for survival, EFS, and FFS. Vertical bars denote 95% CI of the actuarial rates. (A) Kaplan-Meier estimates of EFS of all patients and of randomized patients. Solid black line indicates all patients, 4-year rate, 90.2%; dotted line, randomized patients, 4-year rate from start of treatment, 92.4% (92.2% from time of randomization). (B) Kaplan-Meier estimates of EFS according to cyclophosphamide dose randomization in the second COPADM course. Black line indicates full-dose CPM in second COPADM, 4-year rate, 93.4%; gray line, half-dose CPM in second COPADM, 4-year rate, 90.9% (C) Kaplan-Meier estimates of EFS according to maintenance course M1 randomization. Black line indicates with M1, 4-year rate, 91.9%; gray line, without M1, 4-year rate, 92.5%. (D) Kaplan-Meier estimates of EFS according to the 4 arms of randomization. COPADM1-2, M1 (standard), 4-year rate, 92.5%; COPADM1-2, no M1, 4-year rate, 94.4%; 2 COPADM1, M1, 4-year rate, 91.3%; 2 COPADM1, no M1, 4-year rate, 90.5.